Cargando…

Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life

BACKGROUND: Despite medical advancements, pain is a major source of suffering at the end of life for patients with a solid metastatic cancer. We aimed to assess the trajectory of pain prevalence, severity, interference, and inadequacy of analgesia during the last year of life. METHODS: We analysed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhry, Isha, Shafiq, Mahham, Teo, Irene, Ozdemir, Semra, Malhotra, Chetna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488613/
https://www.ncbi.nlm.nih.gov/pubmed/36147456
http://dx.doi.org/10.2147/JPR.S375874
_version_ 1784792697362448384
author Chaudhry, Isha
Shafiq, Mahham
Teo, Irene
Ozdemir, Semra
Malhotra, Chetna
author_facet Chaudhry, Isha
Shafiq, Mahham
Teo, Irene
Ozdemir, Semra
Malhotra, Chetna
author_sort Chaudhry, Isha
collection PubMed
description BACKGROUND: Despite medical advancements, pain is a major source of suffering at the end of life for patients with a solid metastatic cancer. We aimed to assess the trajectory of pain prevalence, severity, interference, and inadequacy of analgesia during the last year of life. METHODS: We analysed data from the last year of life of 345 decedents from a prospective cohort study of 600 patients with a solid metastatic cancer in Singapore. Patients were surveyed every 3 months and their pain outcomes (prevalence, severity, and interference) and inadequacy of analgesia were analysed. We used mixed-effects regressions to assess the association of pain outcomes with patients’ time from death, demographics, and planned or unplanned hospitalisations. RESULTS: Prevalence of pain was higher in the last 2 months (65%) compared to 11 to 12 months (41%) before death. Pain severity and interference scores (mean ± SD) were also higher in the last month (severity: 2.5±2.6; interference: 2.6±3.0) compared to 12 months before death (severity: 1.4±2.0; interference: 1.4±2.0). At any time during the last year of life, 38% of the patients were prescribed non-steroidal anti-inflammatory drugs, 11% were prescribed weak-opioids and 29% were prescribed strong opioids. These analgesics were prescribed through either oral, topical or injectable route. Pain outcomes were significantly worse (p-value<0.05) for younger patients, those with higher education, and more financial difficulties, while interference was higher after an unplanned hospitalisation in the last month. Females reported higher pain severity score during their last year of life compared to males. For patients reporting moderate to severe pain, inadequacy of analgesia was lower in the last 2 months (43%) compared to 11 to 12 months before death (83%). CONCLUSION: Findings highlight the need for greater attention in monitoring and treatment of pain even earlier in the disease trajectory, and increased attention to patients discharged from an unplanned hospitalisation.
format Online
Article
Text
id pubmed-9488613
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94886132022-09-21 Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life Chaudhry, Isha Shafiq, Mahham Teo, Irene Ozdemir, Semra Malhotra, Chetna J Pain Res Short Report BACKGROUND: Despite medical advancements, pain is a major source of suffering at the end of life for patients with a solid metastatic cancer. We aimed to assess the trajectory of pain prevalence, severity, interference, and inadequacy of analgesia during the last year of life. METHODS: We analysed data from the last year of life of 345 decedents from a prospective cohort study of 600 patients with a solid metastatic cancer in Singapore. Patients were surveyed every 3 months and their pain outcomes (prevalence, severity, and interference) and inadequacy of analgesia were analysed. We used mixed-effects regressions to assess the association of pain outcomes with patients’ time from death, demographics, and planned or unplanned hospitalisations. RESULTS: Prevalence of pain was higher in the last 2 months (65%) compared to 11 to 12 months (41%) before death. Pain severity and interference scores (mean ± SD) were also higher in the last month (severity: 2.5±2.6; interference: 2.6±3.0) compared to 12 months before death (severity: 1.4±2.0; interference: 1.4±2.0). At any time during the last year of life, 38% of the patients were prescribed non-steroidal anti-inflammatory drugs, 11% were prescribed weak-opioids and 29% were prescribed strong opioids. These analgesics were prescribed through either oral, topical or injectable route. Pain outcomes were significantly worse (p-value<0.05) for younger patients, those with higher education, and more financial difficulties, while interference was higher after an unplanned hospitalisation in the last month. Females reported higher pain severity score during their last year of life compared to males. For patients reporting moderate to severe pain, inadequacy of analgesia was lower in the last 2 months (43%) compared to 11 to 12 months before death (83%). CONCLUSION: Findings highlight the need for greater attention in monitoring and treatment of pain even earlier in the disease trajectory, and increased attention to patients discharged from an unplanned hospitalisation. Dove 2022-09-16 /pmc/articles/PMC9488613/ /pubmed/36147456 http://dx.doi.org/10.2147/JPR.S375874 Text en © 2022 Chaudhry et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Chaudhry, Isha
Shafiq, Mahham
Teo, Irene
Ozdemir, Semra
Malhotra, Chetna
Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title_full Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title_fullStr Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title_full_unstemmed Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title_short Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life
title_sort epidemiology of pain among patients with solid metastatic cancer during the last year of life
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488613/
https://www.ncbi.nlm.nih.gov/pubmed/36147456
http://dx.doi.org/10.2147/JPR.S375874
work_keys_str_mv AT chaudhryisha epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife
AT shafiqmahham epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife
AT teoirene epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife
AT ozdemirsemra epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife
AT malhotrachetna epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife
AT epidemiologyofpainamongpatientswithsolidmetastaticcancerduringthelastyearoflife